alexa
Reach Us +1-504-608-2390
Randomized Controlled Trial of Treatment of Chronic Kidney Disease of Uncertain Aetiolgy with Enalapril | OMICS International | Abstract
ISSN: 2161-0495

Journal of Clinical Toxicology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article

Randomized Controlled Trial of Treatment of Chronic Kidney Disease of Uncertain Aetiolgy with Enalapril

Mathu Selvarajah1, Shanthi Mendis2*, Saroj Jayasinghe3, Rezvi Sheriff4, Tilak Abeysekera5 and Firdosi Mehta6

1Department of Nephrology, Teaching Hospital Anuradhapura, Sri Lanka

2Department of Management of Noncommunicable Diseases, World Health Organization, Geneva, Switzerland

3Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Sri Lanka

4Faculty of Medicine, University of Colombo, Sri Lanka

5Nephrology Unit, General Hospital (Teaching), Kandy, Sri Lanka

6World Health Organization, Colombo, Sri Lanka

*Corresponding Author:
Dr. Shanthi Mendis
Department of Management of Noncommunicable Diseases
World Health Organization
Geneva, Switzerland
Tel: 0041 22 791 3441
Fax: 0041 22 791 4151
E-mail: [email protected]

Received date: September 17, 2015; Accepted date: February 19, 2016; Published date: February 28, 2016

Citation: Selvarajah M, Mendis S, Jayasinghe S, Sheriff R, Abeysekera T, et al. (2016) Randomized Controlled Trial of Treatment of Chronic Kidney Disease of Uncertain Aetiolgy with Enalapril. J Clin Toxicol 6:281. doi: 10.4172/2161-0495.1000281

Copyright: © 2016 Selvarajah M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: A double blind placebo controlled randomized trial was conducted to investigate the effect of angiotensin-converting-enzyme (ACE) inhibitor enalapril on the progression of Chronic Kidney Disease (CKD) caused by chronic exposure to nephrotoxins. Methods: 263 people aged 18-70 years diagnosed with CKD stages I, II or III who were not taking ACE inhibitors, who had no other chronic disease or contraindication for treatment with ACE inhibitors, were randomly assigned to enalapril or placebo. The main outcomes were albumin to creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR). Results: The mean systolic and diastolic blood pressure levels declined significantly in both enalapril and placebo groups with no significant difference in the two groups. There was a significant improvement in the albumin to creatinine ratio in the enalapril group compared to the placebo group (p<0.005). In the enalapril group, the mean albumin to creatinine ratio declined from 162.0 mg/g (SD 321.7) at baseline, to 55.4 mg/g (SD 122.4) at one year follow up; while in the placebo group, the mean albumin to creatinine ratio increased from 197.9 mg/g (SD 461.6) at baseline to 253.2 mg/g (SD 558.7), at one year follow up. In both groups, the eGFR declined significantly, during the 12 month follow-up, lower in the enalapril group, although with no significant difference. In the enalapril group the mean (eGFR) declined from 71.7 ml/min (SD 22.2) to 57.1 ml/min (SD16.1), while in the placebo group the mean eGFR declined from 73.8 ml/min (SD 24.2) to 54.7 ml/min (SD 20.3). Conclusion: Enalapril is beneficial in reducing albuminuria in patients with chronic kidney disease of uncertain aetiology.

Keywords

Top